Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT ID: NCT01597375

Last Updated: 2019-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2016-12-14

Brief Summary

The investigators are doing this research study to find out if giving a drug called prasugrel, which is used to prevent blood clots, can reduce reactions to aspirin in people with aspirin exacerbated respiratory disease (AERD), and to learn why taking aspirin every day can work as a treatment for people with AERD. People with AERD have symptoms of asthma, severe runny nose, polyps in the nose, and develop allergic reactions if they take medications like aspirin.

People with AERD can be desensitized to aspirin in order to be able to safely use it daily, but the investigators do not know if prasugrel may prevent reactions to aspirin and provide a safer way for people with AERD to tolerate aspirin.

The investigators also want to understand what is different about the cells and urine from subjects who have AERD, in comparison to subjects who have asthma but do not have AERD and subjects who have allergic rhinitis but do not have asthma. Lastly, the investigators want to understand how aspirin acts differently in subjects who have AERD, in comparison to subjects who have asthma but do not have AERD.

Conditions

Asthma, Aspirin-Induced; Aspirin Exacerbated Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: TRIPLE

Study Groups

Placebo then Prasugrel

Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.

Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined.

Group Type: EXPERIMENTAL

Placebo Oral Tablet

Intervention Type: DRUG

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Prasugrel Oral Tablet

Intervention Type: DRUG

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Prasugrel then Placebo

Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.

Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined.

Group Type: EXPERIMENTAL

Placebo Oral Tablet

Intervention Type: DRUG

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Prasugrel Oral Tablet

Intervention Type: DRUG

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Interventions

Placebo Oral Tablet

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Intervention Type: DRUG

Prasugrel Oral Tablet

Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.

Intervention Type: DRUG

Other Intervention Names

Placebo; Effient

Eligibility Criteria

Inclusion Criteria

• History of physician-diagnosed asthma
• History of nasal polyposis
• History of at least one clinical reaction to oral aspirin or other nonselective COX inhibitor with features of both lower (cough, chest tightness, wheezing, dyspnea) and upper (rhinorrhea, sneezing, nasal obstruction, conjunctival itching and discharge) airway involvement.
• Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose of oral glucocorticoids for at least 3 months, and no history of hospitalization or emergency room visits for asthma for at least the prior 6 months).
• No current smoking, defined as no daily tobacco smoking for at least 6 months and not more than one instance of tobacco smoking in the last 3 months.
• Non-pregnant
• Only those individuals who would otherwise meet clinical qualifications for aspirin desensitization and treatment with high-dose aspirin will be considered for enrollment in the study.

• History of physician-diagnosed asthma.
• No current nasal polyposis confirmed by nasal examination.
• No history of any adverse reaction to aspirin or a COX inhibitor.
• Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose of oral glucocorticoids for at least 3 months, and no history of hospitalization or emergency room visits for asthma for at least the prior 6 months).
• No current smoking
• Non-pregnant

• No history of physician-diagnosed asthma.
• No current nasal polyposis confirmed by nasal examination.
• No history of any adverse reaction to aspirin or a COX inhibitor.
• No current smoking
• Non-pregnant
• Clinical history of symptoms consistent with allergic rhinitis and previously documented allergy to at least one environmental,immunoglobulin E (IgE) testing).
• Normal lung function (baseline FEV1 of 80% of predicted or better).
• A score of 4 or below on the Asthma Screening Questionnaire (33) and negative responses to asthma history questions

Exclusion Criteria

• Current breastfeeding
• History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs
• Hypersensitivity to montelukast or thienopyridines
• History of peptic ulcer disease or gastrointestinal bleed
• Current severe gastro-esophageal reflux disease (GERD), defined as patient currently requiring more than 2 total doses of medication per day to treat persistent symptoms: either more than 2 doses of any single medication type (antacid, proton pump inhibitor, or H2 receptor antagonist), or more than 2 types of medication per day to treat symptoms
• History of systemic or life-threatening respiratory reaction to aspirin requiring intubation or administration of adrenalin
• Current use of any oral beta blocker (due to the risk of bronchospasm associated with beta blockers).
• History of transient ischemic attack or stroke, or diabetes.
• Current presence of uncontrolled hypertension.
• History of hepatic impairment or alcoholism, or evidence of abnormal liver function at Screening Visit. Aspartate transaminase (AST) and alanine transaminase (ALT) levels may not exceed 1.5x the upper limit of normal at Screening Visit (AST may not exceed 52 IU/L, ALT may not exceed 78 IU/L).

• Current breastfeeding
• History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs
• Hypersensitivity to montelukast or thienopyridines
• History of peptic ulcer disease or gastrointestinal bleed
• Current severe GERD
• Current use of any oral beta blocker.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Brigham and Women's Hospital

OTHER

Sponsor Role: collaborator

Elliot Israel, MD

OTHER

Sponsor Role: lead

Responsible Party

Elliot Israel, MD

Director of the Asthma Research Center

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Elliot Israel, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Joshua Boyce, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Locations

Asthma Research Center

Boston, Massachusetts, United States

Countries

United States

Related Links

http://aerd.partners.org/research-studies/clinical-trial-therapeutic-control-of-aspirin-exacerbated-respiratory-disease/

Click here for more info.

Other Identifiers

2010P002961

Identifier Type: -

Identifier Source: org_study_id